Barron's14h
Novo Nordisk A/S ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Patients on Ozempic report ‘waking up blind’ in as little as a day after using jab
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Shein’s London listing at risk as Trump plans US tax changes
Shein and other fast fashion companies could be heavily impacted by new tax changes in the US, which could close a key ...
Nasdaq14d
See Which Of The Latest 13F Filers Holds Novo-Nordisk
At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Novo-Nordisk AS (Symbol: NVO) was held by 9 of these ...
bnnbloomberg15d
Novo Nordisk Shares Have a Long Road Back from 40% Slump
(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of ...
AOL.co.uk15d
Stocks to watch this week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca
In the pharmaceuticals sector, Novo Nordisk is due to report, coming off the back of some positive developments for its weight-loss drugs. Fellow pharma giant AstraZeneca is also set to release ...
Insider Monkey15d
Jim Cramer on Novo Nordisk A/S (NVO): ‘They Don’t Have The Production Capability’
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently talked about. Jim Cramer, the host of Mad Money, has been ...
Mint16d
Are weight-loss drugs like gym memberships? The answer is worth billions
If obesity is a chronic disease, like kidney or heart conditions, demand for GLP-1 drugs shouldn’t ebb and flow with the seasons. But the weight-loss market is far from typical. After analyzing ...
India TV16d
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish ...
Josh Gad reveals he had to stop taking weight-loss drug due to side effects: ‘Really bummed out’
Josh Gad has opened up for the first time about using GLP-1 medication for weight loss and his seesaw experience with the positive and negative side effects.
abc7NY17d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...